Highest-materiality recent filing
Estrella Immunopharma receives Nasdaq bid price deficiency notice for ESLA
Nasdaq notified on Aug 17, 2026 that ESLA bid price stayed below $1.00 for 30 straight days (Jul 6–Aug 14).
Estrella Immunopharma raises $8.0M in registered direct offering and private placement
Gross proceeds of $8.0M from sale of 4,063,290 shares, 1,000,000 pre-funded warrants, and 7,594,935 PIPE common warrants.
Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort
DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).
Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate
100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.
Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M
Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.
Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share
Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).
Estrella Immunopharma receives Nasdaq bid price deficiency notice; faces potential delisting
Nasdaq notified Estrella that common stock failed to maintain $1.00 minimum bid for 30 consecutive days through April 28, 2025.
Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose
First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.
Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target
D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.
Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price
Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.
Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL
First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.
Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024
EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.
Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial
Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.
Merger consideration of $325M; Estrella stockholders receive 32.5M shares; name changes to Estrella Immunopharma.
TradeUP Acquisition Corp. enters $10M PIPE agreements with price adjustment for Estrella merger
Two investors commit $5M each at $10/share; additional shares if VWAP < $8.30 at closing or after 24 months.
TradeUP Acquisition stockholders approve merger with Estrella Biopharma; 650K shares redeemed
Stockholders voted 1,884,258 for vs 631 against to adopt Merger Agreement with Estrella Biopharma.
TradeUP Acquisition enters $6.8M PIPE investment with Suma Ventures for Estrella merger
TradeUP (UPTD) signed binding PIPE term sheet with Suma Ventures to acquire $6.8M payables of Estrella prior to merger closing.
Trust account to liquidate U.S. treasury obligations and money market funds on July 14, 2023; proceeds held in cash to avoid Investment Company Act classification.
TradeUP Acquisition receives Nasdaq extension to Oct 16, 2023 for Public Holder Rule compliance
Nasdaq granted extension until October 16, 2023 to regain compliance with Listing Rule 5550(a)(3).
Company extended deadline to complete initial business combination from May 19 to June 19, 2023.
TradeUP Acquisition Corp. enters $50M common stock purchase agreement with White Lion Capital
Up to $50M in common stock may be sold to White Lion at 97% of VWAP post-business combination with Estrella Biopharma.
TradeUP Acquisition receives Nasdaq deficiency notice for failing minimum public holders rule
Nasdaq notified TradeUP on April 19, 2023 it fails to meet minimum 300 public holders required by Listing Rule 5550(a)(3).
TradeUP Acquisition Corp. receives Nasdaq delisting notice for MVLS below $35M
Nasdaq notified TradeUP on April 3, 2023 that its Market Value of Listed Securities (MVLS) was below $35M for 30 consecutive business days.
On August 14, 2024, the Board of Directors of Estrella Immunopharma, Inc. (the “Company”) appointed Ms. Hong Zhang as Chairperson and a member of the Company’s Board of Directors (the “Board”), effective as of the same date.
Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.
Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.
Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.
Max materiality 0.85 · Median 0.55 · Most common event other_material